This question tests knowledge of federal controlled substance regulations for buprenorphine/naloxone prescriptions. Buprenorphine/naloxone is a Schedule III controlled substance used for opioid use disorder treatment. The correct answer (C) identifies that as a Schedule III controlled substance, it may be refilled up to 5 times within 6 months from the date written under federal law. Option A is incorrect because the DATA 2000 X-waiver requirement was eliminated in January 2023 - prescribers no longer need a special waiver number to prescribe buprenorphine for opioid use disorder. Option B is wrong because Schedule III medications do not require triplicate forms (this applies to Schedule II in some states). Option D is incorrect because buprenorphine/naloxone can be e-prescribed like other controlled substances with appropriate security measures. The clinical pearl is that recent regulatory changes have removed the X-waiver requirement to increase access to buprenorphine treatment, but standard controlled substance regulations still apply including refill limitations and prescription monitoring program requirements.

This question tests recognition of a potentially fatal medication error involving methotrexate dosing frequency. The prescription calls for daily methotrexate for rheumatoid arthritis, which is a serious prescribing error as methotrexate for RA is dosed weekly, not daily. The correct answer (B) requires clarification with the prescriber because daily dosing of methotrexate can cause severe toxicity including bone marrow suppression, hepatotoxicity, and potentially fatal outcomes. Option A is dangerously incorrect - daily methotrexate is never standard for rheumatoid arthritis and has led to numerous deaths. Option C is wrong because it perpetuates the daily dosing error and increases the total dose even further. Option D is incorrect because folic acid supplementation is actually recommended with methotrexate to reduce side effects, not contraindicated. The clinical pearl is that methotrexate for non-oncologic indications (RA, psoriasis) must be dosed weekly, and pharmacists should always verify dosing frequency to prevent this common but potentially fatal error. Many institutions require special labeling and counseling emphasizing "WEEKLY" dosing.

This question tests the regulatory requirements under the iPLEDGE REMS program for isotretinoin due to its high teratogenic risk. The key patient-specific factor is the female patient's childbearing potential, as she is 28 years old and on oral contraceptives. Choice A is the best action because isotretinoin dispensing requires confirmation of iPLEDGE enrollment, authorization, and documentation of pregnancy prevention to ensure compliance and prevent fetal exposure. Choice B is incorrect because isotretinoin is not a Schedule II controlled substance, and choice C is wrong as it has no boxed warning for dependence nor a 7-day supply limit; choice D is suboptimal as isotretinoin is not an opioid requiring naloxone or treatment agreements. Pharmacists must always verify iPLEDGE requirements before dispensing teratogenic medications like isotretinoin. A useful framework is to check for REMS programs when handling high-risk drugs, prioritizing patient safety through regulatory adherence.

This question assesses safety warnings for direct oral anticoagulants like rivaroxaban, focusing on bleeding and adherence. The key patient-specific factor is the patient's recent pulmonary embolism and normal renal function, necessitating vigilant monitoring. Choice B is the best because it emphasizes assessing bleeding risk and counseling on signs of bleeding plus adherence to prevent recurrent thrombosis, aligning with boxed warnings. Choice A is incorrect as rivaroxaban is stable at room temperature; choice C is wrong because rivaroxaban has no REMS requiring weekly labs; choice D is suboptimal as abrupt discontinuation can cause rebound thrombosis. A clinical pearl is to always counsel on bleeding precautions with anticoagulants. Use a framework of evaluating drug-specific risks like bleeding versus thrombosis when dispensing high-risk medications.

This question evaluates federal controlled substance regulations for Schedule II opioids like hydrocodone/acetaminophen. The key patient-specific factor is the patient's age of 67 and chronic pain from osteoarthritis, which may warrant long-term management but must comply with refill restrictions. Choice B is the best because Schedule II medications cannot have refills, requiring new prescriptions to prevent abuse and ensure oversight. Choice A is incorrect as it applies to Schedule III-V substances, not II; choice C is wrong because diagnosis codes do not authorize refills for Schedule II; choice D is suboptimal as pharmacists cannot add refills without direct prescriber authorization. Always verify controlled substance schedules when assessing prescription validity. A decision framework for opioids involves checking for red flags like high quantities and ensuring compliance with DEA rules to mitigate diversion risks.

This question assesses safety considerations for initiating metformin, emphasizing gastrointestinal tolerance. The key patient-specific factor is the patient's new diabetes diagnosis and normal renal function, allowing titration. Choice A is the best because starting low and titrating minimizes GI side effects, promoting adherence and safety. Choice B is incorrect as higher dosing increases intolerance; choice C is wrong because no contraindication exists; choice D is suboptimal as initiation at 1000 mg bid is not mandatory. Start metformin low to go slow for tolerance. A framework involves evaluating patient-specific factors like tolerance risks when adjusting doses.

This question evaluates regulatory restrictions on methadone dispensing for opioid use disorder maintenance. The key patient-specific factor is the patient's opioid use disorder and existing methadone from an opioid treatment program, indicating a controlled setting. Choice B is the best because methadone for OUD is restricted to certified programs, requiring verification to prevent improper dispensing and ensure compliance. Choice A is incorrect as outpatient pharmacies cannot dispense it for OUD without restrictions; choice C is wrong because methadone is Schedule II; choice D is suboptimal as it misapplies identification requirements. Verify prescriber and setting for restricted opioids. A framework involves confirming indication and regulatory allowances for controlled substances in addiction treatment.

This question examines acetaminophen safety warnings in liver disease, focusing on dose limits. The key patient-specific factor is the patient's compensated cirrhosis with elevated liver markers, increasing toxicity risk. Choice C is the best because clarifying a reduced daily limit like 2g and avoiding duplicates prevents hepatotoxicity. Choice A is incorrect as limits are needed; choice B is wrong because ibuprofen may worsen liver issues; choice D is suboptimal as increasing dose heightens risks. Limit acetaminophen to 2g/day in liver disease. A framework involves assessing organ function and adjusting doses for hepatotoxic drugs.

This question tests controlled substance regulations for Schedule II stimulants like amphetamine/dextroamphetamine. The key patient-specific factor is the young adult's ADHD, requiring strict oversight to prevent misuse. Choice B is the best because no refills are allowed for Schedule II, ensuring compliance and reducing diversion. Choice A is incorrect as it applies to Schedule III; choice C is wrong because transfers are limited; choice D is suboptimal as diagnosis codes are not required for validity. Verify no refills on Schedule II prescriptions. A framework is to confirm schedule and refill rules for all controlled substances.

This question evaluates regulatory requirements for non-controlled medications like albuterol, focusing on refill appropriateness. The key patient-specific factor is the patient's COPD and potential overuse with 12 refills, signaling possible poor control. Choice B is the best because refills are allowed but require complete prescriptions, with follow-up for excessive use to ensure safety. Choice A is incorrect as albuterol is not Schedule III; choice C is wrong because it has no REMS; choice D is suboptimal as tamper-resistant paper is for controlled substances. Monitor refill frequency for rescue inhalers. A framework is to assess clinical appropriateness beyond legal validity for chronic therapies.